Business Context and Reporting Period
Propanc Biopharma, Inc., a Delaware corporation with principal executive offices in Australia, filed this Form 8-K on June 26, 2018. The filing reports the entry into a material definitive agreement involving the issuance of a convertible promissory note to secure financing for general working capital purposes.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The specific financial metrics disclosed relate solely to the new debt instrument:
- Principal Amount: $113,000.00
- Net Proceeds Received: $110,000.00 (after a $3,000 deduction for legal expenses)
- Interest Rate: 8% per annum (compounding quarterly after maturity)
- Maturity Date: June 26, 2019 (extendable by up to one year at the lender's discretion)
- Conversion Discount: 65% of the lowest closing bid price over the prior 10 trading days (reduces to 50% if DTC restricted)
- Conversion Cap: Lender cannot convert if ownership exceeds 4.99% of outstanding shares
Material Changes
The primary material change is the creation of a new direct financial obligation. The Company incurred a liability of $113,000, receiving $110,000 in net cash. This represents a new debt instrument with aggressive prepayment penalties and conversion features that could significantly dilute existing shareholders if converted.
Guidance, Risks, and Unusual Items
Management Commentary: The Company intends to use the net proceeds for general working capital. No specific operational guidance or future revenue outlook is provided in this filing.
Risks and Contingencies:
- Prepayment Penalties: Early repayment carries significant premiums ranging from 135% to 145% of the face amount plus accrued interest, depending on the timing of prepayment.
- Default Provisions: Upon default, interest increases to 18% per annum. Default penalties include a 5% increase in the conversion discount for the first three defaults and liquidated damages of $250 per day for failure to issue shares within three business days.
- Dilution Risk: The conversion price is based on a discount to the lowest closing bid price, and the Company must reserve shares equal to four times the amount required for full conversion.
Investor Verification Checklist
- Verify the current outstanding share count to assess the potential dilution impact of the 4.99% conversion cap.
- Review the Company's cash position to determine the ability to service the 8% interest or meet the high prepayment premiums if refinancing is needed.
- Confirm the Company's status as a "Current Information" designated company on the OTC Markets to avoid default triggers related to reporting failures.
- Monitor the stock price volatility, as the conversion price is tied to the lowest closing bid price over a 10-day period.